Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer

Phase 2TerminatedNCT00099879

Bristol-Myers Squibb

Overview

The purpose of this clinical research study is to learn if BMS-275183 can shrink or slow the growth of the cancer in subjects with non-small cell lung cancer (NSCLC). The safety of this treatment will also be studied.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Conditions

Non-small Cell Lung Cancer

Interventions

BMS-275183DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Advanced or metastatic pretreated NSCLC * Measurable disease * Adequate hematologic, hepatic and renal functions * ECOG Performance Status of 0-2 Exclusion Criteria: * Inability to swallow capsules * Recent significant cardiovascular disease * Woman who are pregnant or breastfeeding

Locations (20)

Local Institution

Sacramento, California, United States

Local Institution

New Haven, Connecticut, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.